<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Efficacy and Safety of Topiramate for Essential Tremor</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
				<availability status="unknown"><p>Copyright Ovid Technologies (Wolters Kluwer Health)</p>
				</availability>
				<date type="published" when="2015-10">2015-10</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Kuo-Hsuan</forename><surname>Chang</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>PhD</roleName><forename type="first">Shu-Hui</forename><surname>Wang</surname></persName>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD, MS</roleName><forename type="first">Ching-Chi</forename><surname>Chi</surname></persName>
							<email>chingchi@cgmh.org.tw</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">College of Medicine</orgName>
								<orgName type="department" key="dep2">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Chang Gung University (K-HC, C-CC)</orgName>
								<orgName type="institution" key="instit2">Chang Gung Memorial Hospital</orgName>
								<address>
									<settlement>Linkou</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Far Eastern Memorial Hospital</orgName>
								<orgName type="department" key="dep3">Centre for Evidence-Based Medicine and Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">Taoyuan (K-HC)</orgName>
								<orgName type="institution" key="instit2">New Taipei (S-HW)</orgName>
								<orgName type="institution" key="instit3">Chang Gung Memorial Hospital</orgName>
								<address>
									<settlement>Chiayi</settlement>
									<country>Taiwan (C-CC</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Dermatology</orgName>
								<address>
									<addrLine>Chang Gung Memorial Hospital, Chiayi, 6, Sec West, Chia-Pu Rd</addrLine>
									<postCode>61363</postCode>
									<settlement>Puzih</settlement>
									<region>Chiayi</region>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Efficacy and Safety of Topiramate for Essential Tremor</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Medicine</title>
						<title level="j" type="abbrev">Medicine</title>
						<idno type="ISSN">0025-7974</idno>
						<imprint>
							<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
							<biblScope unit="volume">94</biblScope>
							<biblScope unit="issue">43</biblScope>
							<biblScope unit="page">e1809</biblScope>
							<date type="published" when="2015-10" />
						</imprint>
					</monogr>
					<idno type="DOI">10.1097/md.0000000000001809</idno>
					<idno type="PMID">26512577</idno>
					<idno type="PMCID">PMC4985391</idno>
					<note type="submission">Received: July 25, 2015; revised: September 4, 2015; accepted: September 17, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T21:03+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>AE = adverse event</term>
					<term>AMPA = 2-amino-3-(3hydroxy-5-methyl-isoxazol-4-yl) propanoic acid</term>
					<term>CI = confidence interval</term>
					<term>ET = essential tremor</term>
					<term>GABA = g-aminobutyric acid</term>
					<term>MD = mean difference</term>
					<term>RCT = randomized controlled trial</term>
					<term>RD = risk difference</term>
					<term>TRS = Fahn-Tolosa-Marin tremor rating scale</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Essential tremor (ET) is the most common movement disorder that is frequently treated by propranolol or primidone. However, 30% of patients with ET do not respond to either propranolol or primidone. The objective of this study was to assess the efficacy and safety of topiramate for ET. We searched the MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for relevant randomized controlled trials on the effects of topiramate for ET. A meta-analysis technique was applied to estimate the efficacy and safety of topiramate. The primary outcome was the change in the Fahn-Tolosa-Marin tremor rating scale (TRS). The secondary outcomes included the respective change in the location, motor tasks/function and function disability scores, and adverse events. We included 3 randomized controlled trials with a total of 294 participants. Topiramate was significantly better than placebo in reducing TRS of patients with ET (mean difference [MD] À8.58, 95% confidence interval [CI] À15.46 to À1.70). Changes from the scales of upper limb tremor severity (MD À5.12, 95% CI À7.79 to À2.45), motor tasks/function (MD À5.07, 95% CI À7.12 to À3.03), and functional disability (MD À4.72, 95% CI À6.77 to À2.67) were significantly greater with topiramate than with placebo. More participants taking topiramate experienced adverse events leading to withdrawal than those taking placebo (risk difference 19%, 95% CI 11%-27%). There is consistent evidence supporting the efficacy of topiramate in treating ET; however, a significant proportion of participants withdrew due to its adverse effects.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>E ssential tremor (ET) is the most common movement disorder, affecting about 5% of those age 60 years or older. <ref type="bibr" target="#b0">1</ref> ET usually affects both upper extremities and may involve the head, lower limbs, neck, and voice. <ref type="bibr" target="#b0">1</ref> A small amount of alcohol temporarily ameliorate the tremor, <ref type="bibr" target="#b1">2</ref> frequently leading to excessive alcohol intake in ET patients. <ref type="bibr" target="#b2">3</ref> Propranolol and primidone are considered the first-line treatments for ET. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b4">5</ref> However, it has been estimated that 30% of patients with ET do not respond to either propranolol or primidone. <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> Propranolol may cause fatigue, muscle weakness, impotence, and sleep disorders. Propranolol is contraindicated in patients with asthma and heart block and has clinical interactions with other drugs frequently used by the elderly, such as digoxin, calcium channel blockers, and antiarrhythmics. <ref type="bibr" target="#b8">9</ref> Primidone causes dizziness. Its active metabolite, phenobarbital, interferes with the metabolism of many drugs including warfarin. <ref type="bibr" target="#b8">9</ref> Hence, there is a need for alternative treatment options for ET.</p><p>Topiramate is an anticonvulsant medication with several different mechanisms of action including enhancement of the g-aminobutyric acid (GABA) activity, carbonic anhydrase inhibition, antagonism of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid (AMPA)/kainite receptors, and blockade of voltage-dependent calcium and sodium channels. <ref type="bibr" target="#b9">10</ref> Topiramate has been approved for use in epilepsy and migraine prophylaxis, <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref> though not for ET yet. Based on the limited data from clinical trials, topiramate may lead to significant tremor reduction and improved functional disability compared with placebo, <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> and has been proposed as a potential treatment of ET. <ref type="bibr" target="#b16">17</ref> On the other hand, adverse effects, including concentration deficit, paresthesia, and nausea, were common in the patients treated with topiramate. <ref type="bibr" target="#b17">18</ref> A systemic review is thus needed to clarify the evident level of topiramate in treating ET. Herein, we conducted a systemic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of topiramate in treating ET.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head><p>We searched the MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for relevant RCTs from inception to May 9, 2015. We used a search strategy that combined ''topiramate'' and ''tremor.'' When searching the MEDLINE and EMBASE, we applied the RCT search filters devised by the Cochrane Collaboration. <ref type="bibr" target="#b18">19</ref> The complete search strategy is listed in the Supporting Information. The inclusion criteria of studies were RCTs that assessed the efficacy of topiramate in treating ET and reported useable data that could be extracted to assess the following outcomes. The primary outcome was the change in the overall score of the Fahn-Tolosa-Marin tremor rating scale (TRS). <ref type="bibr" target="#b19">20</ref> The secondary outcomes were the respective change in the location, motor tasks/function, function disability subscales, and adverse events (AEs).</p><p>Two authors (KC and CC), who were not blinded to the names of authors and institutions, screened the search results and selected relevant trials independently. One author (CC) extracted data from the relevant trials and used the Cochrane Collaboration tool for assessing risk of bias to evaluate the quality of the included trials. <ref type="bibr" target="#b18">19</ref> Another author (KC) checked the data and quality assessment. Disagreement was resolved by discussion, with a third author available for arbitration (SW).</p><p>We conducted a meta-analysis to obtain the pooled intervention effect estimates. We expressed the estimates as mean difference (MD) and 95% confidence interval (CI) for continuous outcomes, and as risk difference (RD) and 95% CI for dichotomous outcomes. We calculated the I 2 statistic to assess the degree of statistical heterogeneity across the included trials. A fixe-model was applied when there was no or low heterogeneity (I 2 &lt; 50%), while a random-effects model was applied when there was substantial heterogeneity (I 2 ! 50%). <ref type="bibr" target="#b18">19</ref> We used the Review Manager 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark, 2012) for meta-analysis.</p><p>This study used published data and thus ethical approval was not necessary.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Description of Studies</head><p>The PRISMA study flow chart is shown in <ref type="figure" target="#fig_0">Figure 1</ref>. A total of 117 records were identified from our search and 2 additional records were obtained after screening relevant reviews. Five RCTs were identified from these records. We selected studies that had assessed primary outcomes by TRS during the followup. One RCT was excluded owing to the lack of TRS assessment. <ref type="bibr" target="#b14">15</ref> The data of 1 RCT 21 were repeatedly used in another publication; <ref type="bibr" target="#b15">16</ref> therefore, we only included the latter in this metaanalysis. A total of 3 RCTs with 294 participants met our inclusion criteria and were included. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b15">16</ref> The characteristics of these included trials are shown in <ref type="table" target="#tab_0">Table 1</ref>. All the included trials were of moderate quality when appraised by using the Cochrane Collaboration tool for assessing risk of bias in randomized trials ( <ref type="figure" target="#fig_1">Figure 2</ref>). <ref type="bibr" target="#b18">19</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy</head><p>The efficacy estimates of topiramate in ET are presented in <ref type="figure" target="#fig_2">Figure 3</ref>. All 3 included trials reported the Fahn-Tolosa-Marin TRS overall score, <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b15">16</ref> with 2 of them reporting the respective scores of the subscales. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b15">16</ref> When compared to placebo, topiramate had a significantly greater reduction in TRS overall score (MD À8.58, 95% CI À15.46 to À1.70, <ref type="figure" target="#fig_2">Figure 3A)</ref>. Also, improvement with topiramate was greater than with placebo in all subscales. Changes from the subscale of upper limb tremor severity were significantly greater with topiramate than with placebo (MD À5.12, 95% CI À7.79 to À2.45, <ref type="figure" target="#fig_2">Figure 3B</ref>). Also, topiramate demonstrated a significant greater reduction in the subscales of motor tasks/function (MD À5.07, 95% CI À7.12 to À3.03, <ref type="figure" target="#fig_2">Figure 3C</ref>) and functional disability (MD À4.72, 95% CI À6.77 to À2.67, <ref type="figure" target="#fig_2">Figure 3D</ref>) than placebo.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p>Two included trials reported data on AEs, <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b15">16</ref> but the other included trial did not. <ref type="bibr" target="#b12">13</ref> The safety data are presented in <ref type="figure" target="#fig_3">Figure 4</ref>. When compared to participants taking placebo, a higher proportion of those taking topiramate withdrew from treatments due to AEs (RD 19%, 95% CI 11%-27%, <ref type="figure" target="#fig_3">Figure 4A</ref>). The following AEs were more frequently reported by participants taking topiramate than those taking placebo: paresthesia (RD 18%, 95% CI 11%-24%, <ref type="figure" target="#fig_3">Figure 4B</ref>), taste perversion (RD 16%, 95% CI 10%-23%, <ref type="figure" target="#fig_3">Figure 4C</ref>), concentration/attention difficulty (RD 13%, 95% CI 4%-22%, <ref type="figure" target="#fig_3">Figure 4D</ref>) decreased appetite (RD 9%, 95% CI 4%-15%, <ref type="figure" target="#fig_3">Figure 4E</ref>), memory difficulty (RD 8%, 95% CI 4%-13%, <ref type="figure" target="#fig_3">Figure 4F</ref>). We found no significant differences between participants taking topiramate and those taking placebo as to the frequency of other AEs such as weight loss, nausea, headache, dizziness, thirst, and upper respiratory tract infection (data not shown). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>The present study found consistent evidence showing that topiramate significantly improved ET, including upper extremity tremor severity, motor task performance, and functional disability. These data support topiramate as an alternative therapeutic option in patients with ET that are unresponsive or who were intolerant to propranolol or primidone. However, the adverse effects of topiramate, including paresthesia, taste perversion, and concentration/attention difficulty, decreased appetite and memory difficulty, led to withdrawal of treatment, raising the concern of tolerability in treating ET with topiramate.</p><p>The observed efficacy of topiramate in treating ET could be explained by one of the proposed mechanisms of action of topiramate, such as modulation of GABA A receptors. <ref type="bibr" target="#b21">22</ref> ET may be caused by a deficiency in the a1-subunit of the GABA A receptor, as demonstrated in a knockout model in mice. <ref type="bibr" target="#b22">23</ref> This animal model overlaps, in some clinical characteristics, with ET in humans, and it seems likely that the model reflects the inherited pathophysiologic processes, where there is a loss of inhibitory neurotransmission by cerebellar Purkinje cells. <ref type="bibr" target="#b22">23</ref> This mechanism elucidates that a dysfunction in the cerebellar GABAergic system in ET, while topiramate could treat ET via enhancement of this GABAergic neurotransmission.</p><p>On the other hand, our study revealed an increased risk of development of AEs, such as sensory changes (paresthesia or taste perversion), cognitive dysfunction (impaired attention, concentration, or memory), or decreased appetite, in the ET participants taking topiramate. Paresthesia or taste perversion induced by topiramate may be related to its carbonic anhydrase inhibition. <ref type="bibr" target="#b17">18</ref> Increased metabolic activities following high-frequency neuronal firings result in an increase in the intracellular concentration of bicarbonate. <ref type="bibr" target="#b23">24</ref> Given the excitatory effect of bicarbonate, it is possible that the inhibition of carbonic anhydrase ameliorates the neuronal excitation. In addition, the ability of topiramate to inhibit carbonic anhydrase is also supposed to be related to the activation of hyperpolarizing K þ conductance and then enhance the electrical stabilization of neurons. <ref type="bibr" target="#b24">25</ref> As a leading cause of drug withdrawal, <ref type="bibr" target="#b25">26</ref> topiramate-induced cognitive dysfunction is an important adverse effect that affects the tolerability of drug compliance. Neuroimaging studies have demonstrated a significant GABAergic potentiation with topiramate, <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28</ref> which may disturb cognitive function by inhibitory enhancement. <ref type="bibr">29 -31</ref> The suppression of appetite by topiramate drives its use in eating disorders. <ref type="bibr" target="#b31">32</ref> It has been shown that stimulation of the lateral hypothalamus by AMPA/kainite agonist causes an intense rapid dose-dependent increase in food intake. <ref type="bibr" target="#b32">33</ref> Thus suppression of AMPA/kainite receptor by topiramate might contribute to decreased appetite. However, this appetite suppression in the patients with ET seemed not to result in the weight reduction, which is reported in the trials of topiramate for other diseases. <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35</ref>   In addition to ET, topiramate is applied to the treatment of migraine, 12 epilepsy, <ref type="bibr" target="#b10">11</ref> and diabetic neuropathy. <ref type="bibr" target="#b35">36</ref> A few well-known complications of topiramate, such as visual events, <ref type="bibr" target="#b36">37</ref> renal calculi, <ref type="bibr" target="#b37">38</ref> and word finding difficulties, <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref> were identified in the trial focusing on these disorders. Ciliochoroidal effusion syndrome, uveitis, and visual field defects were reported in the patients with migraine or epilepsy receiving topiramate treatment. <ref type="bibr" target="#b36">37</ref> The exact mechanism by which topiramate triggers these visual events is not completely understood. Most studies on topiramate and renal calculi are reported from epileptic patients. <ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b41">42</ref> The majority of renal stones reported with topiramate are calcium phosphate or calcium oxalate, <ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b43">44</ref> which is believed to be due to renal tubular acidosis by inhibition of carbonic anhydrase type II and IV in the proximal and distal renal tubules. <ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46</ref> Word-finding difficulties have been described in epileptic and migrainous patients treated with topiramate. <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref> The asymmetry of neurotransmitter systems may explain the greater susceptibility of language areas to antiepileptic drugs containing sulfhydryl residues such as topiramate and zonisamide. <ref type="bibr" target="#b46">47</ref> As a CYP3A4 inducer, topiramate may accelerate the hepatic elimination of oral contraceptives. <ref type="bibr" target="#b47">48</ref> Female patients taking topiramate may at risks of contraceptive failure and unintended pregnancy. These adverse effects need to be attended in topiramate-treated patients with ET as well.</p><p>The interpretation of this meta-analysis may be constrained by publication bias, methodological rigor of the included trials, and statistical accuracy. It is possible that only studies showing a benefit in treating ET with topiramate have been published. However, we could not assess the publication bias by funnel plot because only 3 trials were included. <ref type="bibr" target="#b18">19</ref> The different treatment dosages (maximum dose: 400 mg in 2 trials, <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b15">16</ref> 200 mg in the other trial) <ref type="bibr" target="#b12">13</ref> and experimental duration (24 weeks, <ref type="bibr" target="#b13">14</ref> 10 weeks, <ref type="bibr" target="#b15">16</ref> and 15 days) <ref type="bibr" target="#b15">16</ref> may have affected the estimates of treatment effects. Since this is a meta-analysis of study-level data (instead of an individual patient data metaanalysis), we were unable to adjust for confounding variables. Nevertheless, the baseline characteristics of those taking topiramate and placebo across the 3 included trials were comparable. Topiramate has not been compared to propranolol or to primidone in treating ET. Therefore, the comparative effectiveness of topiramate is unknown.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSIONS</head><p>This meta-analysis included 3 RCTs consistently demonstrating the efficacy of topiramate in treating ET, but also revealing a high risk of adverse effects that may lead to withdrawals. Further studies using more statistically sophisticated </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc>PRISMA study flow chart.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc>Risk of bias of included trials (green refers to low risk of bias, yellow for unclear, and red for high risk of bias).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 3 .</head><label>3</label><figDesc>Efficacy of topiramate in treating essential tremor.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIGURE 4 .</head><label>4</label><figDesc>Safety of topiramate in treating essential tremor.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1 .</head><label>1</label><figDesc>Characteristics of Included Trials</figDesc><table><row><cell>Study Author,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Publication Year</cell><cell>Participants</cell><cell>Interventions</cell><cell>Outcomes</cell><cell>Notes</cell></row><row><cell>Connor et al, 2008 16</cell><cell>62 Patients with symptomatic</cell><cell>Topiramate (400 mg/</cell><cell>Fahn-Tolosa-Marin Tremor</cell><cell>Setting: University Medical</cell></row><row><cell></cell><cell>essential tremor involving the</cell><cell>day or maximum</cell><cell>Rating Scale (TRS) overall score.</cell><cell>Centers. Country: US.</cell></row><row><cell></cell><cell>hands, head, or voice according</cell><cell>tolerated dose) or</cell><cell>Respective scores of location,</cell><cell>Funding source: Ortho-</cell></row><row><cell></cell><cell>to the criteria of the Tremor</cell><cell>placebo for 10 weeks</cell><cell>motor tasks/function, and</cell><cell>McNeil Neurologics, Inc.</cell></row><row><cell></cell><cell>Investigation Group</cell><cell></cell><cell>function disability subscales.</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Adverse events</cell><cell></cell></row><row><cell>Ondo et al, 2006 14</cell><cell>208 Patients with moderate to</cell><cell>Topiramate (400 mg/</cell><cell>TRS overall score. Respective</cell><cell>Setting: University Medical</cell></row><row><cell></cell><cell>severe essential tremor of the</cell><cell>day or maximum</cell><cell>scores of location, motor tasks/</cell><cell>Centers. Country: US.</cell></row><row><cell></cell><cell>upper limbs as defined by the</cell><cell>tolerated dose) or</cell><cell>function, and function disability</cell><cell>Funding source: Ortho-</cell></row><row><cell></cell><cell>Tremor Investigation Group</cell><cell>placebo for 24 weeks</cell><cell>subscales. Adverse events</cell><cell>McNeil Neurologics, Inc.</cell></row><row><cell>Carrasco Vargas et al,</cell><cell>24 Patients with essential tremor in</cell><cell>Topiramate (200 mg/</cell><cell>TRS overall score</cell><cell>Setting: Medical Center.</cell></row><row><cell>2011 13</cell><cell>the hands or arms according to</cell><cell>day or maximum</cell><cell></cell><cell>Country: Spain. Funding</cell></row><row><cell></cell><cell>the criteria of the Tremor</cell><cell>tolerated dose) or</cell><cell></cell><cell>source: Not reported.</cell></row><row><cell></cell><cell>Investigation Group</cell><cell>placebo for 15 days</cell><cell></cell><cell></cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2">| www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>methods may be able to more precisely explore the effect and the optimal dose of topiramate in treating ET. Head-to-head trials comparing topiramate with propranolol or to primidone are needed to obtain their comparative effectiveness.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clinical Subtypes of Essential Tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elan</forename><forename type="middle">D</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Blair</forename><surname>Ford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Livia</forename><forename type="middle">F</forename><surname>Barnes</surname></persName>
		</author>
		<idno type="DOI">10.1001/archneur.57.8.1194</idno>
		<idno type="PMID">10927801</idno>
		<ptr type="open-access" target="https://jamanetwork.com/journals/jamaneurology/articlepdf/777304/noc90166.pdf" />
	</analytic>
	<monogr>
		<title level="j">Archives of Neurology</title>
		<title level="j" type="abbrev">Arch Neurol</title>
		<idno type="ISSN">0003-9942</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">1194</biblScope>
			<date type="published" when="2000-08-01" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The effect of alcohol on essential tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Growdon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">T</forename><surname>Shahani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Young</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.25.3.259</idno>
		<idno type="PMID">1167633</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="259" to="259" />
			<date type="published" when="1975-03-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">High alcoholism rate in patients with essential tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">A</forename><surname>Nasrallah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1471" to="1473" />
			<date type="published" when="1982" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Essential Tremor: Diagnosis and Treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jack</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">M</forename><surname>Swope</surname></persName>
		</author>
		<idno type="DOI">10.1592/phco.23.10.1105.32750</idno>
		<idno type="PMID">14524643</idno>
		<idno type="ark">ark:/67375/WNG-SQPZPQ4T-2</idno>
		<idno type="istexId">CCDA37F0453AAC90F2874B3B44C7BE193E61D6E9</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/b70e/b9b179a7556a4b06b6063b5ff9073ab572d2.pdf" />
	</analytic>
	<monogr>
		<title level="j">Pharmacotherapy</title>
		<title level="j" type="abbrev">Pharmacotherapy</title>
		<idno type="ISSN">0277-0008</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1105" to="1122" />
			<date type="published" when="2003-09" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Benefits and Risks of Pharmacological Treatments for Essential Tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kelly</forename><forename type="middle">E</forename><surname>Lyons</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajesh</forename><surname>Pahwa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cynthia</forename><forename type="middle">L</forename><surname>Comella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mahmood</forename><forename type="middle">S</forename><surname>Eisa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rodger</forename><forename type="middle">J</forename><surname>Elble</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stanley</forename><surname>Fahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><surname>Jankovic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jorge</forename><forename type="middle">L</forename><surname>Juncos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><forename type="middle">C</forename><surname>Koller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><forename type="middle">G</forename><surname>Ondo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kapil</forename><forename type="middle">D</forename><surname>Sethi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">B</forename><surname>Stern</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Caroline</forename><forename type="middle">M</forename><surname>Tanner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ron</forename><surname>Tintner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ray</forename><forename type="middle">L</forename><surname>Watts</surname></persName>
		</author>
		<idno type="DOI">10.2165/00002018-200326070-00003</idno>
		<idno type="PMID">12735785</idno>
	</analytic>
	<monogr>
		<title level="j">Drug Safety</title>
		<title level="j" type="abbrev">Drug Safety</title>
		<idno type="ISSN">0114-5916</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="461" to="481" />
			<date type="published" when="2003" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Survey of medication usage patterns among essential tremor patients: Movement disorder specialists vs. general neurologists</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nancy</forename><forename type="middle">L</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elan</forename><forename type="middle">D</forename><surname>Louis</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.parkreldis.2010.07.011</idno>
		<idno type="PMID">20691629</idno>
		<idno type="PMCID">PMC2963696</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2963696?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Parkinsonism &amp; Related Disorders</title>
		<title level="j" type="abbrev">Parkinsonism &amp; Related Disorders</title>
		<idno type="ISSN">1353-8020</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="604" to="607" />
			<date type="published" when="2010-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Primidone in essential tremor of the hands and head: a double blind controlled clinical study.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Findley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Cleeves</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Calzetti</surname></persName>
		</author>
		<idno type="DOI">10.1136/jnnp.48.9.911</idno>
		<idno type="PMID">3900296</idno>
		<idno type="PMCID">PMC1028493</idno>
		<idno type="ark">ark:/67375/NVC-93K0TRR7-G</idno>
		<idno type="istexId">AAB14628DF3A93E19C3C9243C24C120E5A3D5722</idno>
		<ptr type="open-access" target="https://jnnp.bmj.com/content/jnnp/48/9/911.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Neurology, Neurosurgery &amp; Psychiatry</title>
		<title level="j" type="abbrev">Journal of Neurology, Neurosurgery &amp; Psychiatry</title>
		<idno type="ISSN">0022-3050</idno>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="911" to="915" />
			<date type="published" when="1985-09-01" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Acute and chronic effects of propranolol and primidone in essential tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">C</forename><surname>Koller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Vetere-Overfield</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.39.12.1587</idno>
		<idno type="PMID">2586774</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1587" to="1587" />
			<date type="published" when="1989-12-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Hansten and Horn Managing Clinically Important Drug Interactions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">D</forename><surname>Hansten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Horn</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2003" />
			<publisher>Facts &amp; Comparisons</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Mechanism of action of newer anticonvulsants</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">S</forename><surname>White</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="5" to="8" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Topiramate as Add-On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ross</forename><surname>Reife</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gordon</forename><surname>Pledger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shu-Chen</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1528-1157.2000.tb02175.x</idno>
		<idno type="PMID">10768304</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<title level="j" type="abbrev">Epilepsia</title>
		<idno type="ISSN">0013-9580</idno>
		<idno type="ISSNe">1528-1167</idno>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">s1</biblScope>
			<biblScope unit="page" from="66" to="71" />
			<date type="published" when="2000-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Topiramate for the prophylaxis of episodic migraine in adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mattias</forename><surname>Linde</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wim</forename><forename type="middle">M</forename><surname>Mulleners</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edward</forename><forename type="middle">P</forename><surname>Chronicle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Douglas</forename><forename type="middle">C</forename><surname>Mccrory</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd010610</idno>
		<idno type="PMID">23797676</idno>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database of Systematic Reviews</title>
		<idno type="ISSNe">1465-1858</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">10610</biblScope>
			<date type="published" when="2013-06-24" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prospective double blind study of the use of topiramato vs. placebo in the treatment of essential tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carrasco</forename><surname>Vargas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Castellanos</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aceves</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Neurocir Psiquiatr</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Topiramate in essential tremor: A double-blind, placebo-controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">G</forename><surname>Ondo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Jankovic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Pahwa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Elble</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Stacy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">C</forename><surname>Koller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Schwarzman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Hulihan</surname></persName>
		</author>
		<idno type="DOI">10.1212/01.wnl.0000200779.03748.0f</idno>
		<idno type="PMID">16436648</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="672" to="677" />
			<date type="published" when="2006-01-25" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">A Double-blind, Placebo-controlled, Crossover Trial of Topiramate in Essential Tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nafsika</forename><surname>Frima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">A</forename><surname>Gr??newald</surname></persName>
		</author>
		<idno type="DOI">10.1097/00002826-200603000-00007</idno>
		<idno type="PMID">16614542</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical Neuropharmacology</title>
		<title level="j" type="abbrev">Clinical Neuropharmacology</title>
		<idno type="ISSN">0362-5664</idno>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="94" to="96" />
			<date type="published" when="2006-03" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Tarsy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Neuropharmacol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="97" to="103" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">A</forename><surname>Zesiewicz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Elble</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">D</forename><surname>Louis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Gronseth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">G</forename><surname>Ondo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">B</forename><surname>Dewey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Okun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Weiner</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.0b013e318236f0fd</idno>
		<idno type="PMID">22013182</idno>
		<idno type="PMCID">PMC3208950</idno>
		<ptr type="open-access" target="http://n.neurology.org/content/77/19/1752.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1752" to="1755" />
			<date type="published" when="2011-10-19" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Topiramate in Migraine Prevention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">D</forename><surname>Silberstein</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1526-4610.2005.4501005.x</idno>
		<idno type="PMID">15833091</idno>
		<idno type="ark">ark:/67375/WNG-72JTXN6W-1</idno>
		<idno type="istexId">43D0A083171AED0CB9808A1DCB41997D697BA689</idno>
	</analytic>
	<monogr>
		<title level="j">Headache: The Journal of Head and Face Pain</title>
		<title level="j" type="abbrev">Headache</title>
		<idno type="ISSN">0017-8748</idno>
		<idno type="ISSNe">1526-4610</idno>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">s1</biblScope>
			<biblScope unit="page" from="S57" to="S65" />
			<date type="published" when="2005-04" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main">Cochrane Handbook for Systematic Reviews of Interventions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jpt</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Green</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008" />
			<publisher>Wiley-Blackwell</publisher>
			<pubPlace>Chichester, UK</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Koller</surname></persName>
		</author>
		<title level="m">Movement Disorders: Neurologic Principles and Practice</title>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>McGraw-Hill</publisher>
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A double-blind placebo-controlled trial of topiramate treatment for essential tremor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">S</forename><surname>Connor</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.59.1.132</idno>
		<idno type="PMID">12105323</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="132" to="134" />
			<date type="published" when="2002-07-09" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Comparative Anticonvulsant and Mechanistic Profile of the Established and Newer Antiepileptic Drugs</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">S</forename><surname>White</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1528-1157.1999.tb00913.x</idno>
		<idno type="PMID">10530688</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<title level="j" type="abbrev">Epilepsia</title>
		<idno type="ISSN">0013-9580</idno>
		<idno type="ISSNe">1528-1167</idno>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">s5</biblScope>
			<biblScope unit="page" from="s2" to="s10" />
			<date type="published" when="1999-05" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Genetic essential tremor in γ-aminobutyric acidA receptor α1 subunit knockout mice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jason</forename><forename type="middle">E</forename><surname>Kralic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hugh</forename><forename type="middle">E</forename><surname>Criswell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jessica</forename><forename type="middle">L</forename><surname>Osterman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Todd</forename><forename type="middle">K</forename><surname>O’buckley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mary</forename><forename type="middle">E</forename><surname>Wilkie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Douglas</forename><forename type="middle">B</forename><surname>Matthews</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristin</forename><surname>Hamre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><forename type="middle">R</forename><surname>Breese</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregg</forename><forename type="middle">E</forename><surname>Homanics</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">Leslie</forename><surname>Morrow</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci23625</idno>
		<idno type="PMID">15765150</idno>
		<idno type="PMCID">PMC1052003</idno>
		<ptr type="open-access" target="http://www.jci.org/articles/view/23625/files/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Investigation</title>
		<title level="j" type="abbrev">J. Clin. Invest.</title>
		<idno type="ISSN">0021-9738</idno>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="774" to="779" />
			<date type="published" when="2005-03-01" />
			<publisher>American Society for Clinical Investigation</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Effects of C0 2 on excitatory transmission apparently caused by changes in intracellular pH in the rat hippocampal slice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Junhee</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tomi</forename><surname>Taira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pekka</forename><surname>Pihlaja</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bruce</forename><forename type="middle">R</forename><surname>Ransom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kai</forename><surname>Kaila</surname></persName>
		</author>
		<idno type="DOI">10.1016/0006-8993(95)01214-1</idno>
		<idno type="PMID">8822358</idno>
		<idno type="PII">0006-8993(95)01214-1</idno>
		<idno type="ark">ark:/67375/6H6-BX24VK0J-F</idno>
		<idno type="istexId">D2BFF18F0D55501658149D9B7FDB827ADE256E4D</idno>
	</analytic>
	<monogr>
		<title level="j">Brain Research</title>
		<title level="j" type="abbrev">Brain Research</title>
		<idno type="ISSN">0006-8993</idno>
		<imprint>
			<biblScope unit="volume">706</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="210" to="216" />
			<date type="published" when="1996-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Two new actions of topiramate: inhibition of depolarizing GABAA-mediated responses and activation of a potassium conductance</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ana</forename><forename type="middle">I</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nuria</forename><surname>Del Olmo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José</forename><forename type="middle">R</forename><surname>González-Escalada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>José M. Solı́s</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0028-3908(01)00171-x</idno>
		<idno type="PMID">11804617</idno>
	</analytic>
	<monogr>
		<title level="j">Neuropharmacology</title>
		<title level="j" type="abbrev">Neuropharmacology</title>
		<idno type="ISSN">0028-3908</idno>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="210" to="220" />
			<date type="published" when="2002-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Postmarketing experience with topiramate and cognition</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tatum</forename><surname>Wot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Faught</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1134" to="1140" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Topiramate increases cerebral GABA in healthy humans</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Kuzniecky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Hetherington</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Gilliam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Hugg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Faught</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.51.2.627</idno>
		<idno type="PMID">9710056</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="627" to="629" />
			<date type="published" when="1998-08-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Kuzniecky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Gilliam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Faught</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Hetherington</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.58.3.368</idno>
		<idno type="PMID">11839834</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="368" to="372" />
			<date type="published" when="2002-02-12" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bettina</forename><surname>Gomer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kathrin</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lars</forename><surname>Frings</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Josef</forename><surname>Saar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Astrid</forename><surname>Carius</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Markus</forename><surname>Härle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernhard</forename><forename type="middle">J</forename><surname>Steinhoff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><surname>Schulze-Bonhage</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.yebeh.2007.02.007</idno>
		<idno type="PMID">17409025</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsy &amp; Behavior</title>
		<title level="j" type="abbrev">Epilepsy &amp; Behavior</title>
		<idno type="ISSN">1525-5050</idno>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="486" to="494" />
			<date type="published" when="2007-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jacobus</forename><forename type="middle">F A</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Albert</forename><forename type="middle">P</forename><surname>Aldenkamp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Marian Majoie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rianne</forename><forename type="middle">P</forename><surname>Reijs</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marc</forename><forename type="middle">C T F M</forename><surname>De Krom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">A M</forename><surname>Hofman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Eline Kooi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Klaas</forename><surname>Nicolay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Walter</forename><forename type="middle">H</forename><surname>Backes</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.yebeh.2006.05.004</idno>
		<idno type="PMID">16793345</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsy &amp; Behavior</title>
		<title level="j" type="abbrev">Epilepsy &amp; Behavior</title>
		<idno type="ISSN">1525-5050</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="181" to="185" />
			<date type="published" when="2006-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of Topiramate in epilepsy patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edgar</forename><surname>Kockelmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><forename type="middle">E</forename><surname>Elger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christoph</forename><surname>Helmstaedter</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0920-1211(03)00078-0</idno>
		<idno type="PMID">12837568</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsy Research</title>
		<title level="j" type="abbrev">Epilepsy Research</title>
		<idno type="ISSN">0920-1211</idno>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">2-3</biblScope>
			<biblScope unit="page" from="171" to="178" />
			<date type="published" when="2003-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Topiramate for the Treatment of Binge Eating Disorder Associated With Obesity: A Placebo-Controlled Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><forename type="middle">L</forename><surname>Mcelroy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">I</forename><surname>Hudson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julie</forename><forename type="middle">A</forename><surname>Capece</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karen</forename><surname>Beyers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">C</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Norman</forename><forename type="middle">R</forename><surname>Rosenthal</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biopsych.2006.08.008</idno>
		<idno type="PMID">17258690</idno>
	</analytic>
	<monogr>
		<title level="j">Biological Psychiatry</title>
		<title level="j" type="abbrev">Biological Psychiatry</title>
		<idno type="ISSN">0006-3223</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1039" to="1048" />
			<date type="published" when="2007-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Lateral hypothalamic injections of glutamate, kainic acid,d,l-α-amino-3-hydroxy-5-methyl-isoxazole propionic acid or N-methyl-d-aspartic acid rapidly elicit intense transient eating in rats</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Glenn Stanley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lyen</forename><forename type="middle">H</forename><surname>Ha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lela</forename><forename type="middle">C</forename><surname>Spears</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">G</forename><surname>Dee</surname></persName>
		</author>
		<idno type="DOI">10.1016/0006-8993(93)90458-y</idno>
		<idno type="PMID">7688643</idno>
		<idno type="PII">0006-8993(93)90458-Y</idno>
		<idno type="ark">ark:/67375/6H6-44NLSC0D-1</idno>
		<idno type="istexId">31849E0701C9B23EF1809D1E174DFAAB702FBF64</idno>
	</analytic>
	<monogr>
		<title level="j">Brain Research</title>
		<title level="j" type="abbrev">Brain Research</title>
		<idno type="ISSN">0006-8993</idno>
		<imprint>
			<biblScope unit="volume">613</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="88" to="95" />
			<date type="published" when="1993-06" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Topiramate, nutrition and weight change: a prospective study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Theisen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Knake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Oertel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Hebebrand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Rosenow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">M</forename><surname>Hamer</surname></persName>
		</author>
		<idno type="DOI">10.1136/jnnp.2007.136929</idno>
		<idno type="PMID">18077476</idno>
		<idno type="ark">ark:/67375/NVC-X31XZ24C-2</idno>
		<idno type="istexId">ECD9FA54E5C6562E3A363DF05C3651857111AFA0</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Neurology, Neurosurgery &amp; Psychiatry</title>
		<title level="j" type="abbrev">Journal of Neurology, Neurosurgery &amp; Psychiatry</title>
		<idno type="ISSN">0022-3050</idno>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="590" to="593" />
			<date type="published" when="2008-05-01" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Changes in body mass index during long-term topiramate therapy in paediatric epilepsy patients—a retrospective analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edith</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martha</forename><surname>Feucht</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erwin</forename><surname>Hauser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Freilinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rainer</forename><surname>Seidl</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.seizure.2003.12.001</idno>
		<idno type="PMID">15324828</idno>
	</analytic>
	<monogr>
		<title level="j">Seizure</title>
		<title level="j" type="abbrev">Seizure</title>
		<idno type="ISSN">1059-1311</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="491" to="493" />
			<date type="published" when="2004-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Neuropathic pain: Etiology, pathophysiology, mechanisms, and evaluations</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><forename type="middle">W</forename><surname>Jay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">L</forename><surname>Barkin</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.disamonth.2013.12.001</idno>
		<idno type="PMID">24507705</idno>
	</analytic>
	<monogr>
		<title level="j">Disease-a-Month</title>
		<title level="j" type="abbrev">Disease-a-Month</title>
		<idno type="ISSN">0011-5029</idno>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="6" to="47" />
			<date type="published" when="2014-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Topiramate and the vision: a systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seyed-Hossein</forename><surname>Abtahi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Abtahi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Fazel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Jenab</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peyman</forename><surname>Roomizadeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Etemadifar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Akbari</surname></persName>
		</author>
		<idno type="DOI">10.2147/opth.s27695</idno>
		<idno type="PMID">22275816</idno>
		<idno type="PMCID">PMC3261698</idno>
		<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=11813" />
	</analytic>
	<monogr>
		<title level="j">Clinical Ophthalmology</title>
		<title level="j" type="abbrev">OPTH</title>
		<idno type="ISSNe">1177-5483</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">117</biblScope>
			<date type="published" when="2012-01" />
			<publisher>Dove Medical Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">The Risk and Management of Kidney Stones From the Use of Topiramate and Zonisamide in Migraine and Idiopathic Intracranial Hypertension</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yasmin</forename><forename type="middle">Idu</forename><surname>Jion</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amanda</forename><surname>Raff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brian</forename><forename type="middle">M</forename><surname>Grosberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Randolph</forename><forename type="middle">W</forename><surname>Evans</surname></persName>
		</author>
		<idno type="DOI">10.1111/head.12480</idno>
		<idno type="PMID">25486999</idno>
		<idno type="ark">ark:/67375/WNG-HG7SWR1K-V</idno>
		<idno type="istexId">B5CA8BB735C337B0C6B47F1AF3CC80FEC8C76B80</idno>
	</analytic>
	<monogr>
		<title level="j">Headache: The Journal of Head and Face Pain</title>
		<title level="j" type="abbrev">Headache: The Journal of Head and Face Pain</title>
		<idno type="ISSN">0017-8748</idno>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="161" to="166" />
			<date type="published" when="2014-12-09" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Topiramate and word-finding difficulties in patients with epilepsy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mula</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Trimble</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W A S</forename><surname>Sander</surname></persName>
		</author>
		<idno type="DOI">10.1212/01.wnl.0000056637.37509.c6</idno>
		<idno type="PMID">12682314</idno>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<title level="j" type="abbrev">Neurology</title>
		<idno type="ISSN">0028-3878</idno>
		<idno type="ISSNe">1526-632X</idno>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1104" to="1107" />
			<date type="published" when="2003-04-08" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Language Disturbances as a Side Effect of Prophylactic Treatment of Migraine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francesca</forename><surname>Coppola</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cristiana</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><surname>Luisa Mancini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ilenia</forename><surname>Corbelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Katiuscia</forename><surname>Nardi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Sarchielli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paolo</forename><surname>Calabresi</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1526-4610.2007.00860.x</idno>
		<idno type="PMID">18184290</idno>
		<idno type="ark">ark:/67375/WNG-3XTRZ7KB-S</idno>
		<idno type="istexId">68F7303CA7FCDE0FDEBA672454AC0A3DCB7CAF21</idno>
	</analytic>
	<monogr>
		<title level="j">Headache: The Journal of Head and Face Pain</title>
		<title level="j" type="abbrev">Headache</title>
		<idno type="ISSN">0017-8748</idno>
		<idno type="ISSNe">1526-4610</idno>
		<imprint>
			<biblScope unit="volume">0</biblScope>
			<biblScope unit="issue">0</biblScope>
			<biblScope unit="page" from="070623002213001" to="???" />
			<date type="published" when="2007-06-23" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Safety of Topiramate: Adverse Events and Relationships to Dosing</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simon</forename><forename type="middle">D</forename><surname>Shorvon</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1528-1157.1996.tb06029.x</idno>
		<idno type="PMID">8641242</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<title level="j" type="abbrev">Epilepsia</title>
		<idno type="ISSN">0013-9580</idno>
		<idno type="ISSNe">1528-1167</idno>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">s2</biblScope>
			<biblScope unit="page" from="S18" to="S22" />
			<date type="published" when="1996-08" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Nephrolithiasis in topiramate users</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Naim</forename><forename type="middle">M</forename><surname>Maalouf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joshua</forename><forename type="middle">P</forename><surname>Langston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">C</forename><surname>Van Ness</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Orson</forename><forename type="middle">W</forename><surname>Moe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Khashayar</forename><surname>Sakhaee</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00240-010-0347-5</idno>
		<idno type="PMID">21165738</idno>
		<idno type="PMCID">PMC4103417</idno>
		<idno type="ark">ark:/67375/VQC-P5H6G1BL-0</idno>
		<idno type="istexId">84703337C34171549BB7A779A38C9F10E8C5D8B5</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc4103417?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Urological Research</title>
		<title level="j" type="abbrev">Urol Res</title>
		<idno type="ISSN">0300-5623</idno>
		<idno type="ISSNe">1434-0879</idno>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="303" to="307" />
			<date type="published" when="2010-12-17" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Valentina</forename><forename type="middle">G</forename><surname>Dell'orto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eva</forename><forename type="middle">A</forename><surname>Belotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barbara</forename><surname>Goeggel-Simonetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giacomo</forename><forename type="middle">D</forename><surname>Simonetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gian</forename><forename type="middle">Paolo</forename><surname>Ramelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mario</forename><forename type="middle">G</forename><surname>Bianchetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sebastiano</forename><forename type="middle">A G</forename><surname>Lava</surname></persName>
		</author>
		<idno type="DOI">10.1111/bcp.12283</idno>
		<idno type="PMID">24219102</idno>
		<idno type="PMCID">PMC4093921</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc4093921?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">British Journal of Clinical Pharmacology</title>
		<title level="j" type="abbrev">Br J Clin Pharmacol</title>
		<idno type="ISSN">0306-5251</idno>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="958" to="964" />
			<date type="published" when="2014-05-22" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Patients With and Without Prior Urolithiasis Have Hypocitraturia and Incident Kidney Stones While on Topiramate</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><forename type="middle">M</forename><surname>Kaplon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristina</forename><forename type="middle">L</forename><surname>Penniston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">Y</forename><surname>Nakada</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.urology.2010.06.048</idno>
		<idno type="PMID">20888032</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<title level="j" type="abbrev">Urology</title>
		<idno type="ISSN">0090-4295</idno>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="295" to="298" />
			<date type="published" when="2011-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nagai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Kooh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Balfe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Fenton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Halperin</surname></persName>
		</author>
		<idno type="DOI">10.1007/s004670050354</idno>
		<idno type="PMID">9323296</idno>
		<idno type="ark">ark:/67375/VQC-T0N589M3-L</idno>
		<idno type="istexId">C3A94EBD055BED3D719C869AADE92B7CB3E47F22</idno>
	</analytic>
	<monogr>
		<title level="j">Pediatric Nephrology</title>
		<title level="j" type="abbrev">Pediatric Nephrology</title>
		<idno type="ISSN">0931-041X</idno>
		<idno type="ISSNe">1432-198X</idno>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="633" to="636" />
			<date type="published" when="1997-09-17" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Biochemical and Stone-Risk Profiles With Topiramate Treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brian</forename><forename type="middle">J</forename><surname>Welch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dion</forename><surname>Graybeal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Orson</forename><forename type="middle">W</forename><surname>Moe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Naim</forename><forename type="middle">M</forename><surname>Maalouf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Khashayar</forename><surname>Sakhaee</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.ajkd.2006.07.003</idno>
		<idno type="PMID">16997051</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Kidney Diseases</title>
		<title level="j" type="abbrev">American Journal of Kidney Diseases</title>
		<idno type="ISSN">0272-6386</idno>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="555" to="563" />
			<date type="published" when="2006-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Language Disturbances as Side Effects of Topiramate and Zonisamide Therapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Linda</forename><forename type="middle">M</forename><surname>Ojemann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><forename type="middle">A</forename><surname>Ojemann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carl</forename><forename type="middle">B</forename><surname>Dodrill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><forename type="middle">A</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">D</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donald</forename><forename type="middle">L</forename><surname>Dudley</surname></persName>
		</author>
		<idno type="DOI">10.1006/ebeh.2001.0285</idno>
		<idno type="PMID">12609393</idno>
		<idno type="PII">S1525-5050(01)90285-9</idno>
		<idno type="ark">ark:/67375/6H6-D4SS8SFL-4</idno>
		<idno type="istexId">9C5E39D4666BB5CBA21BE6B235698F16194CB8D5</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsy &amp; Behavior</title>
		<title level="j" type="abbrev">Epilepsy &amp; Behavior</title>
		<idno type="ISSN">1525-5050</idno>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="579" to="584" />
			<date type="published" when="2001-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Effect of Topiramate on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Patients with Epilepsy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><forename type="middle">E</forename><surname>Rosenfeld</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dennis</forename><forename type="middle">R</forename><surname>Doose</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sally</forename><forename type="middle">A</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename><surname>Nayak</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1528-1157.1997.tb01123.x</idno>
		<idno type="PMID">9070594</idno>
	</analytic>
	<monogr>
		<title level="j">Epilepsia</title>
		<title level="j" type="abbrev">Epilepsia</title>
		<idno type="ISSN">0013-9580</idno>
		<idno type="ISSNe">1528-1167</idno>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="317" to="323" />
			<date type="published" when="1997-03" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
